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Abstract
Background: Osteosarcoma (OS) is a bone malignancy which occurs primarily in adolescents. Since it occurs
during a period of rapid growth, genes important in bone formation and growth are plausible modifiers of risk.
Genes involved in DNA repair and ribosomal function may contribute to OS pathogenesis, because they maintain
the integrity of critical cellular processes. We evaluated these hypotheses in an OS association study of genes from
growth/hormone, bone formation, DNA repair, and ribosomal pathways.
Methods: We evaluated 4836 tag-SNPs across 255 candidate genes in 96 OS cases and 1426 controls. Logistic
regression models were used to estimate the odds ratios (OR) and 95% confidence intervals (CI).
Results: Twelve SNPs in growth or DNA repair genes were significantly associated with OS after Bonferroni
correction. Four SNPs in the DNA repair gene FANCM (ORs 1.9-2.0, P = 0.003-0.004) and 2 SNPs downstream of the
growth hormone gene GH1 (OR 1.6, P = 0.002; OR 0.5, P = 0.0009) were significantly associated with OS. One SNP
in the region of each of the following genes was significant: MDM2, MPG, FGF2, FGFR3, GNRH2, and IGF1.
Conclusions: Our results suggest that several SNPs in biologically plausible pathways are associated with OS.
Larger studies are required to confirm our findings.
Background
Osteosarcoma (OS) is the most common primary malig-
nant bone tumor and typically occurs in adolescents and
young adults (Damron et al, 2007; Mascarenhas L, 2006;
Stiller CA, 2006). OS incidence has a bimodal age distri-
bution; the primary peak occurs during adolescence and
a second, much smaller peak is present in the elderly
[1,2]. In young patients, OS incidence correlates with
puberty and bone growth. The peak incidence of both
OS and puberty tend to occur earlier in females. OS
incidence is higher in males, who usually grow taller
than females, and it typically occurs at sites of rapid
bone growth (e.g., the metaphyses of long bones) [1].
The incidence peak in adolescence is followed by a
rapid decline and a plateau when bone growth is com-
plete (after age 24 years) [3]. Several studies have sug-
gested that being taller than average at diagnosis is
associated with increased OS risk [4-11]. A recent meta-
analysis of height at diagnosis and birth-weight as OS
risk factors found that high birth-weight (OR 1.35, 95%
CI 1.01-1.79, compared to average birth-weight subjects)
and being taller than average were significant OS risk
factors (for those ≥90
th percentile of height: OR 2.63,
95% CI 1.98-3.49, compared to those ≤50
th percentile of
height) [12]. In aggregate, these data suggest that growth
and development during puberty, and possibly in utero,
contributes to OS etiology.
OS frequently occurs in several cancer predisposition
syndromes, including Li-Fraumeni Syndrome [13], her-
editary bilateral retinoblastoma [14], Bloom, Werner,
Rothmund Thomson syndromes [15], and Diamond-
Blackfan anemia [16]. It also occurs more frequently in
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majority of OS cases, there is no known predisposing
factor. The data regarding the role of common germline
genetic variation in OS risk are sparse. Positive or sug-
gestive associations have been observed for SNPs in the
vitamin D receptor (VDR; FokI polymorphism) [8],
tumor necrosis factor-alpha (TNF-a; promoter region
-238 SNP) [18], insulin-like growth factor 2 receptor
(IGF2R) [19], Fas [20], transforming growth factor-beta
receptor 1 (TGFBR1) [21], and MDM2 [22] genes, but
no associations were observed for the estrogen receptor
(ER) [8], collagen I[alpha]1 (COL1A1)[ 8 ] ,o rTP53 [23]
genes.
Peak levels of endogenous sex hormones, growth hor-
mones, and IGF-I levels occur during puberty which also
corresponds to peak bone growth rates. It is possible that
variation in genes important in bone development,
growth, and puberty are modifiers of OS risk. In addition,
insulin-like growth factors are known to play critical roles
in carcinogenesis [24,25]. Chromosomal aneuploidy in OS
cells [26,27] and the increased OS risk observed with
genetic syndromes caused by mutations in DNA repair
pathways [e.g., TP53 [13], WRN, BLM, RECQL4 [15]] sug-
gests that variants in DNA repair genes may be asso-
ciated with OS risk. Genes in DNA repair and tumor
suppressor pathways may also contribute to OS patho-
genesis, because they help maintain the integrity of criti-
cal cellular processes and defects in these genes often
lead to carcinogenesis. Diamond-Blackfan anemia is asso-
ciated with an increased frequency of OS and mutations
in ribosomal genes (i.e., RPS19, RPS24 and RPS17)
[16,28]. Thus, it is also feasible that variation in these
genes may contribute to OS risk.
There are numerous genes that contribute to bone
growth and puberty, and DNA repair which could con-
tribute to OS which have not yet been evaluated. We
evaluated these hypotheses in an OS association study
of candidate genes from the following pathways: growth
and hormone metabolism, bone formation, tumor sup-
pressor and DNA repair, and ribosomal. We genotyped
4836 tag-SNPs across 255 candidate genes from these
four pathways in 96 OS cases and 1426 cancer-free con-
trols. This approach identified several SNPs in candidate
genes from biologically plausible pathways that were
associated with OS risk.
Methods
Study design and population
OS cases (n = 101) were derived from the hospital-
based, prospective case-control study, the Bone Disease
and Injury Study of Osteosarcoma (BDISO) [29]. Blood
samples and questionnaire data on individuals were col-
lected at orthopedic surgery departments in 10 United
States medical centers between 1994 and 2000. OS
patients were identified at the time of limb salvage sur-
gery. There were no identified cases of Paget’s disease of
the bone in this study. Orthopedic controls from BDISO
(n = 65) were individuals with benign tumors (26%) and
other non-neoplastic conditions, such as inflammatory
diseases, cysts, and trauma,e x c l u d i n gt h o s ew i t hh i p
fracture or osteoporosis. All individuals were self-
described Caucasians. Institutional review boards at
each of the medical centers approved the protocol and
informed consent was obtained from all study subjects.
An additional 1364 cancer-free control subjects were
derived from the Prostate, Lung, Colorectal, and Ovar-
ian (PLCO) Cancer Screening Trial. Individuals aged
55-74 years were enrolled in the screening trial between
1993 and 2001 from 10 different centers in the U.S. All
subjects in this study were required to have completed a
baseline questionnaire, provided a blood specimen, and
consented to participate in etiologic studies of cancer
and related diseases. Controls were limited to Cauca-
sians living in the continental U.S. without a diagnosis
of adenoma or cancer at baseline. The institutional
review boards at the National Cancer Institute and 10
screening centers approved the study.
Genotyping assays
DNA was isolated from blood specimens using standard
methods. Genotyping was conducted on a Custom Infi-
nium
® BeadChip (iSelect)™ from Illumina, Inc. The iSe-
lect panel was created by investigators in the Division of
Cancer Epidemiology and Genetics, National Cancer
Institute (NCI) to target genetic variation in genes
potentially important in carcinogenesis and cancer risk.
Tag SNPs were identified from the HapMap CEU popu-
lation assuming a r
2 threshold of 0.80 using the Tagzilla
module of the GLU software package (http://code.goo-
gle.com/p/glu-genetics/) across 255 candidate genes,
including the region 20 kb upstream and 10 kb down-
stream from the gene. Additional potentially functional
SNPs were forced into the tag-SNP selection for select
genes. In this study, a total of 6050 tag-SNPs were
genotyped.
The concordance rates between 10 duplicate BDISO
and PLCO samples on the iSelect panel were 99.5% and
99.9%, respectively. SNPs were excluded if they had less
than a 90% genotyping rate in either study population,
were non-variable or had a minor allele frequency
(MAF) <1%, or if they failed the Hardy-Weinberg equili-
brium test or genotyping validation. Individuals were
excluded if they had too much missing genotype data
(>10% missing genotypes). A total of 4836 tag-SNPs met
these quality control criteria and were included for
analysis.
After selecting approximately 500 genetically matched
controls, based on 28 k iSelect SNPs, from our 1426
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all 1426 controls, we determined that there was no sig-
nificant difference in the results; and thus, we used all
1426 controls in our analyses to maximize our ability to
detect associations with rare alleles. A principal compo-
nent analysis was performed using a set of 3,843 struc-
ture inference SNPs selected from the iSelect BeadChip
(27,905 SNPs) to evaluate population substructure
among the BDISO individuals and the PLCO controls.
There was no evidence of significant population stratifi-
cation. However, 5 cases, 2 orthopedic controls and 1
PLCO control were considered genetic outliers and
excluded from the genotyping analyses for a final sample
size of: 96 cases, 63 orthopedic controls, and 1363
PLCO controls.
Statistical analyses
Logistic regression models were used to estimate the
odds ratio (OR) and 95% confidence intervals (CI) for
the strength of the association between OS risk indepen-
dently for each SNP, adjusting for gender. To deal with
rare variants, the most appropriate method was chosen
in the sequence of logistic regression on the additive
trend model, logistic regression on the dominant model,
or the Fisher’s Exact Test. The most common allele or
the homozygote of the common allele was used as the
referent category for the additive or dominant model,
respectively. Bonferroni corrections (Padj)w e r ec o n -
ducted by gene (for all SNPs in a gene) for correction of
multiple statistical tests.
Genes were categorized into biological pathways using
the Kegg pathway database (http://www.genome.jp/kegg/
pathway.html) or by function based on literature review.
We conducted gene-level and pathway-level analyses
based on Yu et al [30]. The gene-level analysis is a glo-
bal test for the association between the outcome and a
subset of SNPs within a given gene or region. The path-
way-level analysis is a global test for the association
between the outcome and any subset of genes within a
given pathway. P-values for these analysis were esti-
mated with 20,000 permutation steps according to the
algorithm given in Yu et al [30].
Statistical analyses were performed using SAS soft-
ware, version 9.1 (SAS Institute, Cary, NC), R language,
and PLINK software, version 1.06 (http://pngu.mgh.har-
vard.edu/purcell/plink/). Wee v a l u a t e dt h ec o r r e l a t i o n
between SNPs [linkage disequilibrium (LD)] across
specific gene regions with Haploview version 4.1 [31].
Results
The characteristics of the study participants are shown
in Table 1. The median age of the 96 OS cases was
20.3 years (age range 8 to 80.5). The median age of the
63 orthopedic controls from the BDISO was 18.5 years
(age range 7.2-68.5), and the PLCO controls were older
with a median age of 62 years (age range 55-75). All
participants were self-identified Caucasians and from
the continental United States. Additional file 1, Table S1
shows the genes analyzed in each pathway, the number
of SNPs and most significant SNP in each gene, and the
gene- and pathway-level P values. There were 161 genes
(2835 SNPs) in the DNA repair pathway, 62 genes (1448
SNPs) in the growth/hormone metabolism pathway, 28
genes (534 SNPs) in the bone formation pathway, and 4
genes (19 SNPs) in the ribosomal pathway. We took
three approaches to the analyses by evaluating associa-
tions with OS at the individual SNP level, gene level,
and pathway level. We used the conservative Bonferroni
correction to correct for multiple statistical tests.
Individual SNPs associated with osteosarcoma
Of the 4836 SNPs, 241 (expected is 241.8) were statisti-
cally significant (P < 0.05) before correction for multiple
tests (Additional file 2, Table S2). A SNP downstream of
GH1 (growth hormone 1) was the most significantly
associated with OS (Ptrend = 0.0009). Twelve SNPs, all in
genes from the DNA repair or growth and hormone
pathways, were significantly associated with OS after
Bonferroni correction (Padj < 0.05) for multiple tests by
gene (for all SNPs in a gene; Table 2 and Figure 1).
T h e r ew e r e4S N P si nt h eD N Ar e p a i rg e n eFANCM
(Fanconi anemia, complementation group M) and 2
SNPs in the growth and hormone gene GH1 that were
significantly associated with OS after correction for mul-
tiple tests. The 4 significant SNPs in FANCM were not
highly correlated using our control data (D’ = 0.93-1.0
and r
2 = 0.01-0.37) and HapMap CEU population data
(Additional file 3, Figure S1). There was high LD among
the 2 significant SNPs downstream of GH1 with our
control data (D’ =0 . 9 6a n dr
2 = 0.91) and HapMap
CEU population data (Additional file 3, Figure S2). In
Figure 1, SNPs in GH1 clearly appear more significant
after correction than SNPs in any other genes. Five
SNPs in the upstream or downstream region of candi-
date genes were significant after correction: downstream
of MDM2 [Mdm2 p53 binding protein homolog
Table 1 Characteristics of cases and controls
mean age
(SD)
n (%)
male
n (%)
female
total
n
OS Cases 26.6 (16.5) 54 (56.3) 42 (43.7) 96
All Controls 60.9 (9.9) 904 (63.4) 522 (36.6) 1426
Orthopedic
Controls
24.7 (15.1) 34 (54.0) 29 (46.0) 63
PLCO Controls 62.6 (5.2) 870 (63.8) 493 (36.2) 1363
n = number of individuals;
SD = standard deviation;
PLCO = Prostate, lung, colon, ovarian cancer cohort.
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Pathway Gene SNP Genomic
position
Minor
Allele
MAF (%)
Controls
MAF (%)
Cases
OR
† 95%
CI
PP adj Model or
Test
§
Gene
P
DNA repair FANCM rs1367580 Chr14:
44714339
Ex14+316
(V878L)
T 10.4 16.7 1.97 (1.26-
3.08)
0.0031 0.034 Dominant 0.019
rs11845507 Chr14:
44721715
IVS16-1012 A 10.5 16.7 1.96 (1.25-
3.06)
0.0033 0.037 Dominant
rs4900664 Chr14:
44732264
IVS20-2861 T 9.3 15.3 2.00 (1.25-
3.17)
0.0035 0.038 Dominant
rs7141145 Chr14:
44733578
IVS20-1547 A 10.3 16.5 1.95 (1.24-
3.07)
0.0039 0.043 Dominant
MDM2 rs1690916 Chr12:
67521673
downstream,
no gene
A 42.5 31.3 0.62 (0.45-
0.85)
0.0029 0.026 Additive 0.016
MPG rs216614 Chr16:
60334
upstream, in
RHBDF1
A 0.7 3.1 4.80 – 0.0036 0.047 Fisher’s 0.027
Growth and
hormone
FGF2 rs11737764 Chr4:
124046230
downstream,
in NUDT6
T 8.1 14.1 2.12 (1.33-
3.39)
0.0016 0.036 Dominant 0.020
FGFR3 rs6599400 Chr4:
1754823
upstream, no
gene
A 33.0 42.6 1.51 (1.12-
2.03)
0.0069 0.021 Additive 0.017
GH1 rs11079515 Chr17:
59359377
downstream,
no gene
G 37.9 49.5 1.61 (1.20-
2.16)
0.0016 0.005 Additive 0.002
rs7921 Chr17:
59359991
downstream,
in CD79B
A 27.2 16.1 0.52 (0.35-
0.76)
0.0009 0.003 Additive
GNRH2 rs3761243 Chr20:
2971022
upstream, no
gene
C 29.7 40.5 1.60 (1.19-
2.16)
0.0020 0.031 Additive 0.021
IGF1 rs7956547 Chr12:
101382946
IVS2+10605 C 26.3 15.8 0.53 (0.36-
0.79)
0.0019 0.040 Additive 0.021
MAF = minor allele frequency;
† Odds ratios were estimated using logistic regression models with the most common allele or genotype as the referent, adjusted for gender;
§ Results are shown for the model or test chosen to deal with rare variants in the sequence of logistic regression on the additive trend model, logistic regression
on the dominant model, or the Fisher’s Exact Test.
Figure 1 Plot of P values for each SNP by functional pathway before and after Bonferroni correction for the number of SNPs per
gene. Inset shows the pathway designations. 4836 SNPs in 255 candidate genes are shown. a = 0.05; dashed line represents an extension of a.
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and upstream of MPG (N-methylpurine-DNA glycosy-
lase), FGFR3 (fibroblast growth factor receptor 3), and
GNRH2 (gonadotropin-releasing hormone 2). A SNP in
intron 2 (IVS2+10605) of IGF1 [insulin-like growth fac-
tor 1 (somatomedin C)] was significantly associated with
a decreased risk of OS after correction.
Genes and pathways associated with osteosarcoma
We evaluated 255 candidate genes from four functional
pathways (Additional file 1, Table S1). Fourteen genes
were significantly associated with OS (Gene P-values
<0.05; Additional file 1, Table S1 and Additional file 2,
Table S2). The most significantly related genes were
GH1 (Gene P = 0.002), MDM2 (Gene P =0 . 0 1 6 ) ,
FGFR3 (Gene P = 0.017), and FANCM (Gene P =
0.019). However, if we correct for multiple tests (255
genes), none remain significant. None of the four path-
ways were significantly associated with OS (Additional
file 1, Table S1).
Discussion
The biology of OS pathogenesis is complex and there
are limited data on risk factors in the more common
sporadic form of OS. Epidemiologic studies of OS sug-
gest that growth and development play a role in etiology
[2,32,33]. It occurs primarily in adolescents during pub-
erty [1] when bone growth is rapid and endogenous sex
hormones and growth hormones are at their highest, so
variation in a gene involved in regulating sex hormones
is biologically plausible. Rapidly growing tissue, such as
bone during puberty, is known to be highly susceptible
to carcinogenesis, possibly due to rapidly proliferating
osteogenic cells being more vulnerable to DNA repair
errors [4,34]. In addition, chromosomal aneuploidy is
extensive in somatic OS cells, which suggests the pre-
sence of chromosomal instability[26,27]. The increased
frequency of OS in genetic predisposition syndromes
[13,15] characterized by mutations in DNA repair path-
ways suggests that variants in genes involved in DNA
repair are also reasonable candidates.
We evaluated the association between OS and 255
candidate genes, including 4836 SNPs, from four func-
tional pathways (growth and hormone metabolism, bone
formation, DNA repair, and ribosomal). We used 3
approaches to comprehensively evaluate these biologi-
cally plausible pathways: analyses were performed at the
individual SNP level, gene level and pathway level with
conservative statistical corrections for multiple testing.
While no genes or pathways were significantly asso-
ciated with OS after correction for multiple tests, the
SNP based approach identified some potentially impor-
tant candidates. A total of twelve SNPs in genes from
the growth and hormone metabolism, and DNA repair
pathways were significantly associated with OS risk after
correction for multiple tests. Two genes had multiple
significant SNPs associated with risk, FANCM and GH1,
after correction for multiple tests.
FANCM contained 4 SNPs significantly associated
with a similar 2-fold increased risk of OS using a domi-
nant inheritance model, the most in any gene studied.
These SNPs were not correlated in our controls. One
SNP is located in exon 14 and the minor or risk allele
results in a nonsynonymous change from valine to leu-
cine (Ex14+316, Val878Leu). The minor allele of this
SNP is the ancestral allele and is highly conserved
among other mammalian species. The three other SNPs
in FANCM were intronic. FANCM has DNA-dependent
ATPase activity, promotes the dissociation of DNA tri-
plexes, and with other Fanconi anemia-associated pro-
teins, may repair DNA at stalled replication forks
[35,36]. DNA repair must be accurate to preserve gen-
ome stability for long-term cellular viability; genetic
instability is characteristic of cancer cells, and may be
due, at least in part, to mutations or variation in genes
that function to ensure DNA integrity [37].
Two significant SNPs were located downstream of
GH1. They appear to be highly correlated in our con-
trols, although one SNP was associated with an
increased risk of OS and the other was protective. The
variant in IGF1 (rs7956547, IVS2+10605) associated
with a decreased risk of OS was another interesting can-
didate involved in growth. The insulin-like growth factor
signaling system is important in the formation and
homeostasis of bone, and differential expression of IGF1
has been observed in osteosarcomas [38-40]. IGFI
expression is stimulated by growth hormone, and OS
incidence peaks during puberty with the release of
growth hormone. OS cells have been shown to be IGF1-
dependent for growth, and inhibiting growth hormone
release in mice decreased IGF1 serum levels and inhib-
ited tumor growth [41-43]. In addition, animal model
data from dogs, which develop OS similar to human
patients (similar sites, histology and treatment response)
and large breeds have a 185-fold increased risk of OS
compared with small dog breeds [44,45], suggest that a
SNP in IGF1 is a main determinant of small size in dogs
and is virtually absent in giant breeds [46]. The data
suggest that GH1 and IGF1 may play a role in the etiol-
ogy of OS.
We also specifically evaluated the genes found to be
associated with OS in other studies. We previously iden-
tified a SNP in IGF2R (rs998075; Ex16+88G >A) to be
significantly associated with OS risk in study of variation
in genes critical in growth regulation [19]. This SNP was
also included in our dataset and the significant associa-
tion replicated in an analysis limited to our BDISO
cases and controls (P = 0.01), as expected because it is
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not replicate with the addition of our 1363 PLCO con-
trols (P = 0.12), which suggests that the original study
may have been limited by the number of controls, or
possibly these older PLCO controls have a different eth-
nic mix within whites related to this polymorphism.
Others have found significanta s s o c i a t i o n sb e t w e e nO S
and polymorphisms in VDR [8], TGFBR1 [21], and
MDM2 [22], which were also included in our dataset.
We found no significant associations with individual
SNPs within VDR or TGFBR1 before or after correction
for multiple tests, although our dataset did not include
the VDR FokI polymorphism [8] or TGFBR1*6A variant
[21], or at the gene level. One SNP downstream of the
DNA repair gene MDM2, rs1690916, was significantly
associated with a decreased risk of OS after correction
(OR 0.62, 95% CI 0.45-0.85, Padj = 0.026), and 3 intronic
SNPs were significantly associated with an increased
risk of OS before correction (ORs 1.6-1.8, P = 0.008-
0.02). The previously identified [22]MDM2 T309G
(rs2279744) polymorphism was marginally non-signifi-
cantly associated with an increased risk of OS (OR 1.31,
95% CI 0.97-1.77, P = 0.07). At the gene level, MDM2
was found to be significantly associated with OS (Gene
P = 0.016), but not after correction for multiple tests.
As others have shown [8,23], the current study did not
confirm associations between polymorphisms in ESR1/2
(including previously analyzed PvuII and XbaI poly-
morphisms), COL1A1,o rTP53 and OS after correction,
or at the gene level.
We also investigated many of the genes with germline
mutations in cancer predisposition syndromes associated
with an increased frequency of OS [15], including the
DNA repair genes TP53 (mutated in Li-Fraumeni Syn-
drome), WRN (mutated in Werner syndrome), BLM
(mutated in Bloom syndrome), RECQL4 (mutated in
Rothmund-Thomson Syndrome), and the ribosomal
genes RPS19 and RPS24 (mutated in Diamond-Blackfan
anemia) [28,47,48]. OS also occurs more commonly in
older individuals with Paget’s disease[17]. Two genes
involved in bone formation, SQSTM1 and TNFRSF11A,
have been shown to cause Paget’s disease [49]. We
found that no common SNPs within these genes that
predispose to cancer predisposition syndromes or
Paget’s disease were significantly associated with OS
after correction for multiple tests.
A limitation of the current study was the small num-
ber of cases; however, the inclusion of 14 controls per
case improved the statistical power to detect SNPs with
strong effects. For the additive model and our 96 cases
and 1426 controls, we had greater than 80% statistical
power to detect an OR of 1.82 for MAFs of 0.1 and an
OR of 2.15 for MAFs of 0.05 (with a baseline population
risk of 0.0000001 and type 1 error of 0.05). Another
potential limitation of our study was the use of controls
from PLCO that were older than the BDISO case and
control population. However, the PLCO controls had no
history of any cancer, including osteosarcoma, they were
limited to Caucasians from the continental US, as were
the BDISO cases and controls, and we found no evi-
dence of population stratification in between groups.
Strengths of the current study include the detailed
genotyping of biologically plausible pathways which give
a higher a priori likelihood. We used three statistical
approaches to comprehensively evaluate associations
with OS (at the SNP level, gene level, and pathway
level). In addition, we used a stringent Bonferroni cor-
rection and conservatively interpreted our results to
reduce the probability of a Type 1 error.
Conclusions
We have conducted the largest study of genetic varia-
tion in candidate genes associated with OS to date. We
identified the presence of genetic variants in candidate
genes from biologically plausible pathways important in
growth and hormone metabolism, and DNA repair asso-
ciated with OS, even with conservative statistical correc-
tions. The strongest candidates are FANCM, GH1 and
IGF1. The potential functional implications of the varia-
tion in these genes are currently unknown. However,
since OS occurs during a period of rapid bone growth,
genes important in growth, puberty, and DNA repair
are biologically plausible contributors to OS pathogen-
esis because of their function in critical cellular pro-
cesses. Larger studies of common genetic variation in
OS and functional studies of the SNPs identified here
are required to confirm the significance of our findings.
Additional material
Additional file 1: Table S1. SNPs from 255 candidate genes by
functional pathway. This table shows the genes analyzed in each
pathway, the number of SNPs in each gene, the P value for the most
significant SNP in each gene, and the gene- and pathway-level P values.
Additional file 2: Table S2. Significant SNPs (P < 0.05) in each pathway
associated with osteosarcoma before correction for multiple tests. This
table lists the statistics (minor allele, MAF, OR, and P values) for each of
the 241 SNPs significantly (P < 0.05) associated with osteosarcoma before
correction for multiple tests by gene and pathway.
Additional file 3: Supplementary Figures S1 and S2. Figure S1.
Linkage disequilibrium across FANCM using the HapMap Caucasian (CEU)
population data (A), and our control data (B) determined using
Haploview. This figure illustrates the linkage disequilibrium across FANCM
and highlights the significant SNPs associated with osteosarcoma after
correction for multiple tests. Figure S2. Linkage disequilibrium across GH1
using the HapMap Caucasian (CEU) population data (A), and our control
data (B) determined using Haploview. This figure illustrates the linkage
disequilibrium across GH1 and highlights the significant SNPs associated
with osteosarcoma after correction for multiple tests
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